The Vanguard Group 13D and 13G filings for Viking Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-12 5:54 pm Unchanged | 2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX | The Vanguard Group | 10,167,614 9.170% | 0 (Unchanged) | Filing |
| 2024-11-04 1:54 pm Purchase | 2024-09-30 | 13G | Viking Therapeutics, Inc. VKTX | The Vanguard Group | 10,167,614 9.170% | 4,785,710 (+88.92%) | Filing |
| 2024-02-13 5:17 pm Purchase | 2023-12-29 | 13G | Viking Therapeutics, Inc. VKTX | The Vanguard Group | 5,381,904 5.380% | 5,381,904 (New Position) | Filing |